Guilin Sanjin (002275.SZ) released its interim report for the first half of 2024, with operating revenue of 1.068 billion yuan, a decrease of 10.53% year-on-year. The net income attributable to shareholders of the listed company was 0.301 billion yuan, a decrease of 20.70% year-on-year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.274 billion yuan, a decrease of 25.21% year-on-year. The basic earnings per share was 0.51 yuan.
桂林三金(002275.SZ)：上半年净利润3.01亿元 同比下降20.70%
Guilin Sanjin Pharmaceutical (002275.SZ): net income of 0.301 billion yuan in the first half of the year, a year-on-year decrease of 20.70%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated